ASSESSMENT OF BONE TISSUE IN PATIENTS WITH PROSTATE CANCER RECEIVING ANDROGEN DEPRIVATION THERAPY AND COMBINED ANTIRESORPTIVE THERAPY

Summary.There were violations of bone mineral density determined by bone densitometry in 82 patients with prostate cancer receiving the hormone therapy. The significant percentage of patients has been diagnosed with osteopenia II-III types (19,7%) and osteoporosis (5,9%), which needed to prescribe the inhibitors of bone resorption. The administration of zolendronic acid in combination with denosumab has showed the significantly beneficial effect on increasing bone mineral density.